Physician profile
Jonathan Fleischmann
NPI 1174539605
$2,267.92
in general payments reported to CMS, 2019-2025
27 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $292 · 2021: $70.03 · 2022: $330 · 2023: $354 · 2024: $63.72 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $542 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $541.98 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $394.85 | 2019-2025 | Veozah, Myrbetriq, Xtandi |
| Abbvie INC. | $197.41 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $183.79 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $166.75 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $160.09 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $126.97 | 2019-2020 | |
| Aytu Biopharma, INC. | $117.61 | 2019-2020 | |
| Axonics, INC. | $114.38 | 2021-2023 | Bulkamid, Axonics |
| Janssen Scientific Affairs, LLC | $111.71 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $111.47 | 2019-2020 | |
| Neotract INC. | $79.26 | 2019 | |
| Pfizer INC. | $69.95 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $58.75 | 2019-2020 | |
| Boston Scientific Corporation | $56.21 | 2020-2025 | Ams 700 |
| Blue Earth Diagnostics | $53.40 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.64 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $35.06 | 2025 | Imfinzi |
| Merck Sharp & Dohme LLC | $33.12 | 2020-2023 | Keytruda, Lynparza |
| Verity Pharmaceuticals INC. | $32.75 | 2023 | Trelstar |
| Urogen Pharma, INC. | $20.80 | 2023 | Jelmyto |
| Photocure INC | $16.89 | 2019 | |
| Allergan, INC. | $14.90 | 2020 | |
| Acerus Pharmaceuticals Corporation | $14.55 | 2022 | |
| Coloplast Corp | $12.93 | 2019 | |
| Olympus America INC. | $12.46 | 2022 | |
| Metuchen Pharmaceuticals | $11.62 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Fleischmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.